HEB Inhibitors
HEB inhibitors constitute a diverse class of compounds that act either directly on HEB or indirectly by modulating key signaling pathways intricately connected to HEB function. GSK-J4 and GSK-J5 exemplify direct inhibitors, specifically targeting lysine-specific demethylase 1 (LSD1) to disrupt the demethylation of histones associated with HEB. This direct inhibition occurs through interference with the epigenetic regulation of HEB, impacting its activity and subsequent cellular responses. Indirect inhibitors include compounds like Trametinib and GDC-0879, which target the mitogen-activated protein kinase (MEK) pathway, disrupting downstream signaling cascades involving HEB. These inhibitors interfere with the MAPK/ERK-dependent regulation of HEB, affecting its activation and cellular responses. Bromodomain and extra-terminal (BET) protein inhibitors, such as BAY 1238097 and JQ1, directly influence HEB by inhibiting BET proteins. These compounds disrupt the interaction of BET proteins with chromatin associated with HEB, modulating its function.
XAV939 and GSK-3 Inhibitor XV indirectly modulate HEB through the Wnt/β-catenin pathway. XAV939 inhibits tankyrase, impacting β-catenin degradation and subsequently influencing HEB. GSK-3 Inhibitor XV disrupts glycogen synthase kinase-3 (GSK-3)-mediated regulation of β-catenin, affecting HEB activation. Furthermore, HEB is indirectly influenced by compounds like Xylometazoline and Trifluoperazine. Xylometazoline activates α-adrenergic receptors, influencing HEB through α-adrenergic signaling pathways. Trifluoperazine inhibits calmodulin, disrupting calcium-dependent events associated with HEB. Histone acetyltransferase (HAT) inhibitor C646 directly influences HEB by targeting HAT activity, disrupting the acetylation of histones associated with HEB. In summary, HEB inhibitors offer a nuanced approach, comprising both direct and indirect modulators. Understanding the diverse mechanisms through which these inhibitors influence HEB sheds light on potential strategies for precise modulation of HEB function in various cellular contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 is a lysine-specific demethylase 1 (LSD1) inhibitor that directly modulates HEB by targeting the demethylase activity of LSD1. By inhibiting LSD1, GSK-J4 disrupts the demethylation of histone substrates associated with HEB, directly influencing HEB function. This direct inhibition occurs through the interference with the epigenetic regulation of HEB, affecting its activity and the subsequent cellular responses influenced by HEB signaling. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a mitogen-activated protein kinase (MEK) inhibitor that indirectly modulates HEB through the MAPK/ERK pathway. By inhibiting MEK, Trametinib disrupts the downstream signaling cascades involving HEB, indirectly influencing its function. This indirect modulation occurs through the interference with the MAPK/ERK-dependent regulation of HEB, affecting its activation and the subsequent cellular responses influenced by HEB signaling. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is a tankyrase inhibitor that indirectly modulates HEB through the Wnt/β-catenin pathway. By inhibiting tankyrase, XAV939 disrupts the degradation of Axin1, indirectly influencing HEB function. This indirect modulation occurs through the interference with the Wnt/β-catenin-dependent regulation of HEB, affecting its activation and the subsequent cellular responses influenced by HEB signaling. | ||||||
GDC-0879 | 905281-76-7 | sc-364497 | 5 mg | $225.00 | ||
GDC-0879 is a mitogen-activated protein kinase (MEK) inhibitor that indirectly modulates HEB through the MAPK/ERK pathway. By inhibiting MEK, GDC-0879 disrupts the downstream signaling cascades involving HEB, indirectly influencing its function. This indirect modulation occurs through the interference with the MAPK/ERK-dependent regulation of HEB, affecting its activation and the subsequent cellular responses influenced by HEB signaling. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is a bromodomain and extra-terminal (BET) protein inhibitor that directly influences HEB through the inhibition of BET proteins. By targeting BET proteins, JQ1 disrupts their interaction with chromatin associated with HEB, directly modulating HEB function. This direct inhibition occurs through the interference with the epigenetic regulation of HEB, affecting its activity and the subsequent cellular responses influenced by HEB signaling. | ||||||
TAE684 | 761439-42-3 | sc-364626 sc-364626A | 5 mg 50 mg | $188.00 $988.00 | 2 | |
NVP-TAE 684 is a receptor tyrosine kinase (RTK) inhibitor that indirectly modulates HEB through RTK signaling pathways. By inhibiting RTKs, NVP-TAE 684 disrupts the downstream signaling cascades involving HEB, indirectly influencing its function. This indirect modulation occurs through the interference with RTK-dependent regulation of HEB, affecting its activation and the subsequent cellular responses influenced by HEB signaling. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646 is a histone acetyltransferase (HAT) inhibitor that directly influences HEB through the inhibition of HAT activity. By targeting HAT, C646 disrupts the acetylation of histones associated with HEB, directly modulating HEB function. This direct inhibition occurs through the interference with the epigenetic regulation of HEB, affecting its activity and the subsequent cellular responses influenced by HEB signaling. | ||||||